CU20160077A7 - Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo - Google Patents

Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo

Info

Publication number: CU20160077A7
Authority: CU; Cuba
Prior art keywords: pirrolo; piridinyl; pyrazinyl; pyrimidinyl; acrylic
Prior art date: 2013-12-05

Application number

CU20160077A

Other languages

English (en)

Other versions

CU24396B1 (es

Inventor

Matthew Frank Brown

Agustin Casimiro-Garcia

Ye Che

Jotham Wadsworth Coe

Mark Edward Flanagan

Adam Matthew Gilbert

Matthew Merrill Hayward

Jonathan David Langille

Justin Ian Montgomery

Jean-Baptiste Telliez

Atli Thorarensen

Rayomand Jal Unwalla

John I Trujillo

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-05

Filing date

2014-11-20

Publication date

2017-01-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52144776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20160077(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-11-20 Application filed by Pfizer filed Critical Pfizer

2017-01-10 Publication of CU20160077A7 publication Critical patent/CU20160077A7/es

2019-04-04 Publication of CU24396B1 publication Critical patent/CU24396B1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Psychology (AREA)
Obesity (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)

CU2016000077A 2013-12-05 2014-11-20 Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo CU24396B1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361912074P	2013-12-05	2013-12-05
PCT/IB2014/066202 WO2015083028A1 (en)	2013-12-05	2014-11-20	Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides

Publications (2)

Publication Number	Publication Date
CU20160077A7 true CU20160077A7 (es)	2017-01-10
CU24396B1 CU24396B1 (es)	2019-04-04

Family

ID=52144776

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CU2016000077A CU24396B1 (es)	2013-12-05	2014-11-20	Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo

Country Status (47)

Country	Link
US (3)	US9617258B2 (es)
EP (2)	EP3318565B1 (es)
JP (2)	JP6192839B2 (es)
KR (1)	KR101930603B1 (es)
CN (2)	CN107417684A (es)
AP (1)	AP2016009269A0 (es)
AR (1)	AR099363A1 (es)
AU (1)	AU2014358792C1 (es)
BR (1)	BR112016012262B1 (es)
CA (1)	CA2932425C (es)
CL (1)	CL2016001216A1 (es)
CR (1)	CR20160250A (es)
CU (1)	CU24396B1 (es)
CY (3)	CY1119778T1 (es)
DK (2)	DK3318565T3 (es)
DO (1)	DOP2016000124A (es)
EA (1)	EA030472B1 (es)
ES (2)	ES2654051T3 (es)
FI (1)	FIC20230035I1 (es)
FR (1)	FR23C1042I2 (es)
GE (1)	GEP20186840B (es)
GT (1)	GT201600098A (es)
HR (2)	HRP20171846T1 (es)
HU (3)	HUE054560T2 (es)
IL (1)	IL246038B (es)
LT (2)	LT3318565T (es)
MA (1)	MA39092B1 (es)
MD (1)	MD4649C1 (es)
ME (1)	ME02883B (es)
MX (1)	MX368464B (es)
MY (1)	MY187446A (es)
NI (1)	NI201600075A (es)
NL (1)	NL301245I2 (es)
NO (2)	NO3134430T3 (es)
NZ (1)	NZ720092A (es)
PE (1)	PE20161246A1 (es)
PH (1)	PH12016500938A1 (es)
PL (2)	PL3318565T3 (es)
PT (2)	PT3077395T (es)
RS (2)	RS56728B1 (es)
SI (2)	SI3077395T1 (es)
SV (1)	SV2016005209A (es)
TN (1)	TN2016000227A1 (es)
TW (1)	TWI548636B (es)
UA (1)	UA117040C2 (es)
UY (1)	UY35861A (es)
WO (1)	WO2015083028A1 (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112016005881A2 (pt)	2013-09-18	2017-09-12	Beijing Hanmi Pharmaceutical Co Ltd	composto, composição farmacêutica e uso do composto
CU24396B1 (es) *	2013-12-05	2019-04-04	Pfizer	Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo
WO2016000615A1 (en) *	2014-07-02	2016-01-07	Sunshine Lake Pharma Co., Ltd.	Heteroaryl compounds and pharmaceutical applications thereof
WO2016030443A1 (en)	2014-08-28	2016-03-03	Asceneuron Sa	Glycosidase inhibitors
CN105712998B (zh) *	2014-12-05	2019-12-13	上海润诺生物科技有限公司	氮杂吲哚类衍生物、其制备方法及其在医药上的应用
US9695200B2 (en) *	2015-01-23	2017-07-04	Confluence Life Sciences, Inc.	Heterocyclic ITK inhibitors for treating inflammation and cancer
CN105837574B (zh) *	2015-02-02	2018-03-02	四川大学	N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途
US10703756B2 (en) *	2015-05-01	2020-07-07	Pfizer Inc.	Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof
PT3305788T (pt) *	2015-05-29	2020-09-25	Wuxi Fortune Pharmaceutical Co Ltd	Inibidor da janus cinase
CN106432246B (zh) *	2015-08-05	2020-07-07	广东东阳光药业有限公司	杂芳化合物及其在药物中的应用
KR101771219B1 (ko)	2015-08-21	2017-09-05	양지화학 주식회사	야누스 키나제 1 선택적 억제제 및 그 의약 용도
CN108349972B (zh)	2015-11-03	2021-06-08	施万生物制药研发Ip有限责任公司	用于治疗呼吸疾病的jak激酶抑制剂化合物
US9630968B1 (en)	2015-12-23	2017-04-25	Arqule, Inc.	Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
KR20180132060A (ko)	2016-02-25	2018-12-11	아셰뉴론 에스아	피페라진 유도체의 산 부가 염
US11261183B2 (en)	2016-02-25	2022-03-01	Asceneuron Sa	Sulfoximine glycosidase inhibitors
KR20180132629A (ko)	2016-02-25	2018-12-12	아셰뉴론 에스아	글리코시다제 저해제
WO2017144639A1 (en)	2016-02-25	2017-08-31	Asceneuron S. A.	Glycosidase inhibitors
US10961247B2 (en) *	2016-06-30	2021-03-30	Daewoong Pharmaceutical Co., Ltd.	Pyrazolopyrimidine derivatives as kinase inhibitor
EP3504213A4 (en)	2016-08-24	2020-01-15	ArQule, Inc.	AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE
KR102136958B1 (ko) *	2016-11-23	2020-08-26	우시 포춘 파마슈티컬 컴퍼니 리미티드	7H-피롤로[2,3-d]피리미딘 화합물의 결정형, 염형 및 그 제조방법
CA3040981A1 (en) *	2016-11-23	2018-05-31	Bing Liu	Preparation method for and intermediate of pyrrolo six-membered heteroaromatic ring derivative
RU2764980C2 (ru) *	2017-01-20	2022-01-24	Лео Фарма А/С	Бициклические амины в качестве новых ингибиторов jak-киназы
WO2018154133A1 (en)	2017-02-27	2018-08-30	Janssen Pharmaceutica Nv	[1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors
MX388749B (es)	2017-03-09	2025-03-11	Theravance Biopharma R&D Ip Llc	Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak.
CN108794480A (zh) *	2017-04-28	2018-11-13	天津药物研究院有限公司	吡咯并嘧啶类化合物、其制备方法和用途
EP3609498A1 (en)	2017-05-01	2020-02-19	Theravance Biopharma R&D IP, LLC	Methods of treatment using a jak inhibitor compound
AR111495A1 (es)	2017-05-01	2019-07-17	Theravance Biopharma R&D Ip Llc	Compuestos de imidazo-piperidina fusionada como inhibidores de jak
US10251874B2 (en)	2017-05-01	2019-04-09	Theravance Biopharma R&D Ip, Llc	Crystalline forms of a JAK inhibitor compound
KR20200036004A (ko)	2017-08-01	2020-04-06	세라밴스 바이오파마 알앤디 아이피, 엘엘씨	Jak 키나아제 억제제로서 피라졸로 및 트리아졸로 비시클릭 화합물
EP3672959A1 (en)	2017-08-24	2020-07-01	Asceneuron SA	Linear glycosidase inhibitors
US10981906B2 (en)	2017-11-03	2021-04-20	Aclaris Therapeutics, Inc.	Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same
CA3079848A1 (en) *	2017-11-07	2019-05-16	The Regents Of The University Of Michigan	Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use
CN107857778B (zh) *	2017-11-21	2020-03-24	江苏乐斯化学有限公司	含膦酰基的α-氨基腈的制备方法
KR102577242B1 (ko) *	2017-12-28	2023-09-11	주식회사 대웅제약	카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102577241B1 (ko) *	2017-12-28	2023-09-11	주식회사 대웅제약	카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
NZ764644A (en) *	2017-12-28	2023-06-30	Daewoong Pharmaceutical Co Ltd	Oxy-fluoropiperidine derivative as kinase inhibitor
US11365188B2 (en) *	2018-03-21	2022-06-21	Xibin Liao	JAK inhibitors
CN108358797A (zh) *	2018-04-20	2018-08-03	南京农业大学	一种烷基甘氨酸的合成方法
CN108640923A (zh) *	2018-07-09	2018-10-12	湖南天地恒制药有限公司	一种托法替布关键中间体的制备方法
US12090149B2 (en)	2018-08-06	2024-09-17	Moexa Pharmaceuticals Limited	SMAD3 inhibitors
BR112021002479A2 (pt)	2018-08-10	2021-07-27	Aclaris Therapeutics, Inc.	composto, composição farmacêutica, método para inibir a atividade de itk ou jak3 em uma população de células, método para tratar um distúrbio mediado por itk ou jak3 em um indivíduo necessitando do mesmo e uso de um composto
US12016852B2 (en)	2018-08-22	2024-06-25	Asceneuron Sa	Pyrrolidine glycosidase inhibitors
US11731972B2 (en)	2018-08-22	2023-08-22	Asceneuron Sa	Spiro compounds as glycosidase inhibitors
ES2954474T3 (es)	2018-08-22	2023-11-22	Asceneuron Sa	Sales de adición de ácido de succinato y fumarato de derivados de piperazina útiles como inhibidores de glucosidasa
WO2020039028A1 (en)	2018-08-22	2020-02-27	Asceneuron S. A.	Tetrahydro-benzoazepine glycosidase inhibitors
BR112021004087A2 (pt)	2018-09-04	2021-05-25	Theravance Biopharma R&D Ip, Llc	processo para preparar inibidores de jak e seus intermediários
IL281150B2 (en)	2018-09-04	2024-03-01	Theravance Biopharma R& D Ip Llc	5 to 7 membered heterocyclic amides as jak inhibitors
FI3837258T3 (fi)	2018-09-04	2024-05-27	Theravance Biopharma R&D Ip Llc	Dimetyyliaminoatsetidiiniamideja jak-estäjinä
WO2020067887A1 (en)	2018-09-24	2020-04-02	Erasmus University Medical Center Rotterdam	Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses
JP6944496B2 (ja) *	2018-10-22	2021-10-06	ファイザー・インク	ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
BR112021007788A8 (pt)	2018-10-29	2022-04-26	Theravance Biopharma R&D Ip Llc	Composto inibidor de jak 2-azabiciclo hexano
EP3914348A1 (en)	2019-01-23	2021-12-01	Theravance Biopharma R&D IP, LLC	Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
JP7248256B2 (ja) *	2019-03-14	2023-03-29	上海華匯拓医薬科技有限公司	Ｊａｋキナーゼ阻害剤及びその調製方法、並びにその医薬分野での使用
EP3946606B1 (en) *	2019-03-27	2025-01-01	Insilico Medicine IP Limited	Bicyclic jak inhibitors and uses thereof
US11420966B2 (en) *	2019-05-02	2022-08-23	Aclaris Therapeutics, Inc.	Substituted pyrrolopyridines as JAK inhibitors
EP3969458A4 (en)	2019-05-13	2023-05-17	Borah, Inc.	CHEMICAL COMPOUNDS
BR112021022682A2 (pt)	2019-05-14	2022-02-22	Provention Bio Inc	Métodos e composições para prevenir diabetes do tipo 1
CN110183455B (zh) *	2019-06-18	2021-04-20	中国医科大学	氮杂双环[3.2.1]辛-3-酮类化合物及其制备方法与其用途
CN112430235B (zh) *	2019-08-26	2024-04-05	东莞市东阳光仿制药研发有限公司	一种pf-06651600中间体的制备方法
KR102228668B1 (ko)	2019-10-08	2021-03-17	(주)부흥산업사	메틸피퍼리딘 아미노피롤로 피리미딘의 제조방법
MX2022005882A (es)	2019-11-14	2022-06-14	Pfizer	Combinaciones de 1-(((2s,3s,4s)-3-etil-4-fluoro-5-oxopirrolidin-2- il)metoxi)-7-metoxiisoquinolin-6-carboxamida y formas de dosis orales.
CN112824381B (zh) *	2019-11-21	2024-04-26	广东东阳光药业股份有限公司	一种哌啶胺的制备方法
CN113121539A (zh) *	2019-12-31	2021-07-16	江苏艾立康医药科技有限公司	一种pf06651600的制备方法
CN115023221B (zh) *	2019-12-31	2024-05-28	辉瑞英国研发有限公司	1-((2s,5r)-5-((7h-吡咯并[2,3-d]嘧啶-4-基)氨基)-2-甲基哌啶-1-基)丙-2-烯-1-酮的稳定立即释放片剂和胶囊制剂
CN113121413B (zh) *	2019-12-31	2024-04-09	江苏艾立康医药科技有限公司	一种jak3酶抑制剂关键中间体的制备方法
CN111138361B (zh) *	2020-01-03	2022-05-06	中国医科大学	取代苯氧基-2-氮杂双环[3.2.1]辛烷类化合物及其制备方法和应用
CN115244055B (zh) *	2020-01-21	2024-09-03	江苏先声药业有限公司	嘧啶并五元环类衍生物及其应用
TW202144343A (zh)	2020-03-02	2021-12-01	美商施萬生物製藥研發 Ip有限責任公司	Jak抑制劑化合物之結晶水合物
KR20220164008A (ko)	2020-04-04	2022-12-12	화이자 인코포레이티드	코로나바이러스 질환 2019를 치료하는 방법
CA3182445A1 (en)	2020-06-11	2021-12-16	Francisco Leon	Methods and compositions for preventing type 1 diabetes
CN111620880B (zh) *	2020-06-15	2022-06-10	江苏艾立康医药科技有限公司	Pf-06651600 dl-酒石酸盐，晶型及其制备方法
CN111620879B (zh) *	2020-06-15	2022-06-10	江苏艾立康医药科技有限公司	Pf-06651600马来酸盐，晶型及其制备方法
WO2022002210A1 (zh) *	2020-07-02	2022-01-06	南京明德新药研发有限公司	嘧啶并吡咯基类氘代化合物
WO2022012587A1 (zh) *	2020-07-14	2022-01-20	苏州晶云药物科技股份有限公司	丙烯酮类化合物的丙二酸盐晶型及其制备方法
CN111995623A (zh) *	2020-08-18	2020-11-27	上海毕得医药科技有限公司	一种7-溴-4-氯-1-甲基-1H-咪唑并[4,5-c]吡啶的合成方法
KR102473645B1 (ko)	2020-08-28	2022-12-05	(주)부흥산업사	(2S,5R)-벤질 5-(t-부톡시카르보닐아미노)-2-메틸피페리딘-1-카르복실레이트의 제조방법
CN113061137B (zh) *	2021-04-02	2022-08-02	广西医科大学	含氮杂环衍生物或其药学上可接受的盐和用途
CN113429427A (zh) *	2021-07-05	2021-09-24	湖南南新制药股份有限公司	杂环化合物及其制备方法和药物用途
KR20240051146A (ko) *	2021-08-25	2024-04-19	항저우 위홍 파마테크 컴퍼니 리미티드	방향족 헤테로고리 화합물, 이를 함유한 약물 조성물 및 이의 응용
WO2023029943A1 (zh) *	2021-09-03	2023-03-09	星药科技(北京)有限公司	一种芳杂环化合物及其制备方法和用途
WO2023151069A1 (zh) *	2022-02-14	2023-08-17	湖南南新制药股份有限公司	吡咯并[2,3-d]六元杂芳环衍生物、其制备方法和药物用途
WO2024084363A1 (en)	2022-10-18	2024-04-25	Pfizer Inc.	Use of patatin-like phospholipase domain-containing protein 3 compounds
AU2023364628A1 (en)	2022-10-18	2025-04-03	Pfizer Inc.	Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
WO2024150110A1 (en)	2023-01-11	2024-07-18	Pfizer Inc.	Compositions and methods for the treatment and/or prevention of type 1 diabetes
CN116120347B (zh) *	2023-01-18	2024-08-23	杭州禹泓医药科技有限公司	芳杂环类化合物的晶型、其组合物、制备方法及其应用
CN116496280B (zh) *	2023-06-25	2023-09-08	北京科翔中升医药科技有限公司	氘代丙烯酰胺类jak3抑制剂药物及用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
TW505646B (en)	1998-06-19	2002-10-11	Pfizer Prod Inc	Pyrrolo [2,3-d] pyrimidine compounds
KR100477818B1 (ko)	1999-12-10	2005-03-22	화이자 프로덕츠 인코포레이티드	피롤로[2,3-ｄ] 피리미딘 화합물
BR0111561A (pt) *	2000-06-26	2003-09-09	Pfizer Prod Inc	Composto pirrolo[2,3-d] pirimidina como agentes imunossupressores
US7301023B2 (en)	2001-05-31	2007-11-27	Pfizer Inc.	Chiral salt resolution
KR100742012B1 (ko)	2002-11-21	2007-07-23	화이자 프로덕츠 인코포레이티드	3-아미노-피페리딘 유도체 및 그의 제조 방법
AR054416A1 (es) *	2004-12-22	2007-06-27	Incyte Corp	Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
CN102127078A (zh)	2005-07-14	2011-07-20	安斯泰来制药株式会社	Janus激酶3的杂环类抑制剂
NZ565363A (en)	2005-07-29	2010-03-26	Pfizer Prod Inc	Pyrrolo[2,3-D]pyrimidine derivatives; their intermediates and synthesis
WO2007062459A1 (en)	2005-11-29	2007-06-07	Cytopia Research Pty Ltd	Selective kinase inhibitors based on pyridine scaffold
BRPI0619817B8 (pt)	2005-12-13	2021-05-25	Incyte Corp	composto 3-ciclopentil-3-[4-(7h-pirrol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrila e sua composição
PT2529622T (pt)	2006-09-22	2018-04-24	Pharmacyclics Llc	Inibidores de tirosina cinase de bruton
JO3041B1 (ar)	2008-07-25	2016-09-05	Galapagos Nv	مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
CA2731368C (en)	2008-08-06	2013-05-14	Pfizer Inc.	6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
MX2011002484A (es)	2008-09-05	2011-09-26	Avila Therapeutics Inc	Algoritmo para diseñar inhibidores irreversibles.
ES2545541T3 (es)	2008-10-31	2015-09-11	Genentech, Inc.	Compuestos de pirazolopirimidina inhibidores de JAK y métodos
SG171956A1 (en)	2008-12-05	2011-07-28	Hoffmann La Roche	Pyrrolopyrazinyl urea kinase inhibitors
JOP20190230A1 (ar)	2009-01-15	2017-06-16	Incyte Corp	طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
ES2659725T3 (es)	2009-05-05	2018-03-19	Dana-Farber Cancer Institute, Inc.	Inhibidores de EGFR y procedimiento de tratamiento de trastornos
JO3030B1 (ar)	2009-06-26	2016-09-05	Galapagos Nv	مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
EP2881034B1 (en)	2009-06-30	2020-06-10	Edwards Lifesciences Corporation	Monitoring and displaying a patient's status
UA110324C2 (en)	2009-07-02	2015-12-25	Genentech Inc	Jak inhibitory compounds based on pyrazolo pyrimidine
CA2767079A1 (en) *	2009-07-08	2011-01-13	Leo Pharma A/S	Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors
AP2011006045A0 (en)	2009-08-07	2011-12-31	Metaleach Ltd	Method for leaching cobalt from oxidised cobalt ores.
WO2011029046A1 (en)	2009-09-04	2011-03-10	Biogen Idec Ma Inc.	Bruton's tyrosine kinase inhibitors
EP2509600B1 (en) *	2009-12-09	2017-08-02	Agios Pharmaceuticals, Inc.	Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
UY33213A (es)	2010-02-18	2011-09-30	Almirall Sa	Derivados de pirazol como inhibidores de jak
BR112012029437A2 (pt)	2010-05-20	2017-03-07	F Hoffmann - La Roche Ag	derivados de pirrolo[2,3-b]pirazina-7-carboxamida e seu uso como inibidores de jak e syk
TW201204732A (en) *	2010-07-09	2012-02-01	Leo Pharma As	Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
EP2629777B1 (en) *	2010-10-22	2018-12-19	Merck Sharp & Dohme Corp.	Bicyclic diamines as janus kinase inhibitors
WO2013085802A1 (en) *	2011-12-06	2013-06-13	Merck Sharp & Dohme Corp.	Pyrrolopyrimidines as janus kinase inhibitors
US9527851B2 (en)	2011-12-21	2016-12-27	Jiangsu Hengrui Medicine Co., Ltd.	Pyrrole six-membered heteroaryl ring derivative, preparation method thereof, and medicinal uses thereof
CN104981247A (zh) *	2012-09-06	2015-10-14	普莱希科公司	用于激酶调节的化合物和方法及其适应症
MX2015006191A (es)	2012-11-16	2015-08-10	Merck Sharp & Dohme	Inhibidores de purina de fosfatidilinositol 3-quinasa delta humana.
WO2014081732A1 (en)	2012-11-20	2014-05-30	Principia Biopharma Inc.	Azaindole derivatives as jak3 inhibitors
CN103896946B (zh) *	2012-12-28	2018-04-03	浙江导明医药科技有限公司	用于预防及治疗多种自身免疫疾病的新化合物
CU24396B1 (es) *	2013-12-05	2019-04-04	Pfizer	Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo
US10144737B2 (en) *	2014-05-19	2018-12-04	Jiangsu Hengrui Medicine Co., Ltd.	Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors

2014
- 2014-11-20 CU CU2016000077A patent/CU24396B1/es unknown
- 2014-11-20 TN TN2016000227A patent/TN2016000227A1/fr unknown
- 2014-11-20 EP EP17200940.9A patent/EP3318565B1/en active Active
- 2014-11-20 RS RS20180008A patent/RS56728B1/sr unknown
- 2014-11-20 BR BR112016012262-3A patent/BR112016012262B1/pt active IP Right Grant
- 2014-11-20 HU HUE17200940A patent/HUE054560T2/hu unknown
- 2014-11-20 NZ NZ720092A patent/NZ720092A/en unknown
- 2014-11-20 CR CR20160250A patent/CR20160250A/es unknown
- 2014-11-20 RS RS20210657A patent/RS61897B9/sr unknown
- 2014-11-20 MX MX2016007156A patent/MX368464B/es active IP Right Grant
- 2014-11-20 KR KR1020167017571A patent/KR101930603B1/ko active Active
- 2014-11-20 HU HUE14816404A patent/HUE035264T2/hu unknown
- 2014-11-20 MD MDA20160058A patent/MD4649C1/ro active IP Right Grant
- 2014-11-20 PT PT148164049T patent/PT3077395T/pt unknown
- 2014-11-20 ME MEP-2017-275A patent/ME02883B/me unknown
- 2014-11-20 PT PT172009409T patent/PT3318565T/pt unknown
- 2014-11-20 MA MA39092A patent/MA39092B1/fr unknown
- 2014-11-20 PL PL17200940T patent/PL3318565T3/pl unknown
- 2014-11-20 AP AP2016009269A patent/AP2016009269A0/en unknown
- 2014-11-20 AU AU2014358792A patent/AU2014358792C1/en active Active
- 2014-11-20 PE PE2016000723A patent/PE20161246A1/es unknown
- 2014-11-20 PL PL14816404T patent/PL3077395T3/pl unknown
- 2014-11-20 LT LTEP17200940.9T patent/LT3318565T/lt unknown
- 2014-11-20 DK DK17200940.9T patent/DK3318565T3/da active
- 2014-11-20 CA CA2932425A patent/CA2932425C/en active Active
- 2014-11-20 ES ES14816404.9T patent/ES2654051T3/es active Active
- 2014-11-20 EP EP14816404.9A patent/EP3077395B1/en active Active
- 2014-11-20 ES ES17200940T patent/ES2871524T3/es active Active
- 2014-11-20 CN CN201710579812.XA patent/CN107417684A/zh active Pending
- 2014-11-20 SI SI201430511T patent/SI3077395T1/en unknown
- 2014-11-20 UA UAA201606072A patent/UA117040C2/uk unknown
- 2014-11-20 SI SI201431829T patent/SI3318565T1/sl unknown
- 2014-11-20 EA EA201600373A patent/EA030472B1/ru unknown
- 2014-11-20 GE GEAP201414164A patent/GEP20186840B/en unknown
- 2014-11-20 CN CN201480074974.2A patent/CN106061973B/zh active Active
- 2014-11-20 DK DK14816404.9T patent/DK3077395T3/en active
- 2014-11-20 LT LTEP14816404.9T patent/LT3077395T/lt unknown
- 2014-11-20 WO PCT/IB2014/066202 patent/WO2015083028A1/en active Application Filing
- 2014-11-20 JP JP2016536110A patent/JP6192839B2/ja active Active
- 2014-11-20 MY MYPI2016702037A patent/MY187446A/en unknown
- 2014-12-03 US US14/559,294 patent/US9617258B2/en active Active
- 2014-12-03 UY UY0001035861A patent/UY35861A/es active IP Right Grant
- 2014-12-04 TW TW103142238A patent/TWI548636B/zh active
- 2014-12-04 AR ARP140104517A patent/AR099363A1/es active IP Right Grant
2015
- 2015-04-23 NO NO15721089A patent/NO3134430T3/no unknown
2016
- 2016-05-20 CL CL2016001216A patent/CL2016001216A1/es unknown
- 2016-05-20 PH PH12016500938A patent/PH12016500938A1/en unknown
- 2016-06-03 GT GT201600098A patent/GT201600098A/es unknown
- 2016-06-03 NI NI201600075A patent/NI201600075A/es unknown
- 2016-06-03 DO DO2016000124A patent/DOP2016000124A/es unknown
- 2016-06-03 SV SV2016005209A patent/SV2016005209A/es unknown
- 2016-06-05 IL IL246038A patent/IL246038B/en active IP Right Grant
2017
- 2017-03-01 US US15/446,500 patent/US11111242B2/en active Active
- 2017-08-08 JP JP2017152997A patent/JP2018008996A/ja active Pending
- 2017-11-27 HR HRP20171846TT patent/HRP20171846T1/hr unknown
- 2017-12-18 CY CY20171101325T patent/CY1119778T1/el unknown
2021
- 2021-05-11 CY CY20211100402T patent/CY1124793T1/el unknown
- 2021-05-13 HR HRP20210770TT patent/HRP20210770T1/hr unknown
- 2021-08-04 US US17/393,463 patent/US12077533B2/en active Active
2023
- 2023-10-03 NL NL301245C patent/NL301245I2/nl unknown
- 2023-11-03 FR FR23C1042C patent/FR23C1042I2/fr active Active
- 2023-11-14 HU HUS2300040C patent/HUS2300040I1/hu unknown
- 2023-11-22 FI FIC20230035C patent/FIC20230035I1/fi unknown
2024
- 2024-01-09 NO NO2024001C patent/NO2024001I1/no unknown
- 2024-02-09 CY CY2024002C patent/CY2024002I2/el unknown

Also Published As

Publication number	Publication date
MX368464B (es)	2019-10-02
WO2015083028A1 (en)	2015-06-11
PT3077395T (pt)	2018-01-03
NO3134430T3 (es)	2018-08-18
PH12016500938B1 (en)	2016-06-27
BR112016012262B1 (pt)	2021-04-13
CA2932425E (en)	2015-06-11
KR101930603B1 (ko)	2018-12-18
ES2871524T3 (es)	2021-10-29
AP2016009269A0 (en)	2016-06-30
HRP20210770T1 (hr)	2021-06-25
LT3318565T (lt)	2021-06-25
KR20160092012A (ko)	2016-08-03
US12077533B2 (en)	2024-09-03
CR20160250A (es)	2016-09-19
HRP20171846T1 (hr)	2018-01-12
RS56728B1 (sr)	2018-03-30
TWI548636B (zh)	2016-09-11
PT3318565T (pt)	2021-05-28
IL246038A0 (en)	2016-08-02
CY2024002I1 (el)	2024-09-20
AR099363A1 (es)	2016-07-20
CU24396B1 (es)	2019-04-04
CY1124793T1 (el)	2022-11-25
EA030472B1 (ru)	2018-08-31
DK3318565T3 (da)	2021-05-25
CN106061973A (zh)	2016-10-26
UY35861A (es)	2015-07-31
RS61897B1 (sr)	2021-06-30
CA2932425C (en)	2018-07-17
GT201600098A (es)	2019-10-17
MA39092B1 (fr)	2018-09-28
BR112016012262A2 (pt)	2020-06-30
JP2016539137A (ja)	2016-12-15
NI201600075A (es)	2016-08-09
EP3318565B1 (en)	2021-04-14
AU2014358792C1 (en)	2021-08-26
MD4649B1 (ro)	2019-09-30
MD20160058A2 (ro)	2016-11-30
CN106061973B (zh)	2019-07-09
CN107417684A (zh)	2017-12-01
DOP2016000124A (es)	2016-10-31
PE20161246A1 (es)	2016-11-25
JP6192839B2 (ja)	2017-09-06
MA39092A1 (fr)	2018-06-29
RS61897B9 (sr)	2021-09-30
IL246038B (en)	2020-10-29
MY187446A (en)	2021-09-22
EP3318565A1 (en)	2018-05-09
HUE054560T2 (hu)	2021-09-28
ME02883B (me)	2018-04-20
AU2014358792B2 (en)	2017-06-08
FR23C1042I1 (fr)	2023-12-29
FR23C1042I2 (fr)	2024-11-15
CA2932425A1 (en)	2015-06-11
PH12016500938A1 (en)	2016-06-27
EA201600373A1 (ru)	2016-10-31
FIC20230035I1 (fi)	2023-11-22
UA117040C2 (uk)	2018-06-11
PL3077395T3 (pl)	2018-04-30
GEP20186840B (en)	2018-04-10
US11111242B2 (en)	2021-09-07
CL2016001216A1 (es)	2017-01-20
CY1119778T1 (el)	2018-06-27
TN2016000227A1 (fr)	2017-10-06
HUS2300040I1 (hu)	2023-12-28
SI3077395T1 (en)	2018-03-30
EP3077395B1 (en)	2017-11-15
US20230009153A1 (en)	2023-01-12
HUE035264T2 (hu)	2018-05-02
EP3077395A1 (en)	2016-10-12
US20150158864A1 (en)	2015-06-11
AU2014358792A1 (en)	2016-06-02
ES2654051T3 (es)	2018-02-12
CY2024002I2 (el)	2024-09-20
NL301245I2 (nl)	2023-11-20
JP2018008996A (ja)	2018-01-18
TW201524977A (zh)	2015-07-01
LT3077395T (lt)	2018-02-12
MD4649C1 (ro)	2020-04-30
NZ720092A (en)	2019-05-31
SV2016005209A (es)	2018-04-11
PL3318565T3 (pl)	2021-10-04
US9617258B2 (en)	2017-04-11
NO2024001I1 (no)	2024-01-09
MX2016007156A (es)	2016-07-21
DK3077395T3 (en)	2018-01-02
SI3318565T1 (sl)	2021-07-30
US20170247372A1 (en)	2017-08-31

Publication	Publication Date	Title
FR23C1042I2 (fr)	2024-11-15	Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides
HK1220974A1 (zh)	2017-05-19	三氟甲基取代的稠合嘧啶類及其用途
HK1226056A1 (zh)	2017-09-22	吡唑並化合物及其用途
HK1215845A1 (zh)	2016-09-23	多次使用的氣霧生成系統
ZA201507874B (en)	2017-09-27	2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors
EP2991605A4 (en)	2016-12-07	ABSORBENT GARMENT
BR112014028330A2 (pt)	2018-04-17	artigo absorvente tendo extremidade de cintura característica.
HUE051933T2 (hu)	2021-03-29	Egyszer használatos nedvszívó termékek
HK1213167A1 (zh)	2016-06-30	吸收性物品
SG11201401607QA (en)	2014-07-30	Absorbent article
IL247622B (en)	2018-02-28	Turning a query into a vertical-based selector
HK1219962A1 (zh)	2017-04-21	人抗白細胞介素- 抗體
EP2952163A4 (en)	2016-08-10	ABSORBENT ARTICLE
PT2980096T (pt)	2018-11-20	Métodos de preparação de 2,3,5 tri-hidroxi-androst-6-ona e utilização do mesmo
GB201322203D0 (en)	2014-01-29	Deens' merger
FR3006595B1 (fr)	2015-07-17	Article d'electrostimulation musculaire
BR302013001825S1 (pt)	2014-06-03	"configuração aplicada em carrinho de brinquedo"
GB201315043D0 (en)	2013-10-02	Perception intelligent agent